Assoc Prof. Darren Poon, Assoc Prof. Edmund Chiong, 20210114000000
Metastatic hormone-sensitive prostate cancer (mHSPC) refers to the condition whereby patients have metastatic prostate cancer and no prior hormonal therapy or androgen deprivation therapy (ADT). Typically, patients with mHSPC have been treated with ADT alone, following which, the overwhelming majority develop castration resistance over time and head towards eventual mortality. In recent years, the publication of various landmark trials has prompted dramatic changes in the mHSPC treatment landscape, and had favourably impacted overall survival (OS) in these patients. At a recent webinar, A/Prof Darren Poon, Honorary Consultant in Clinical Oncology, Hong Kong Sanatorium & Hospital, and Honorary Clinical Associate Professor, Department of Clinical Oncology, The Chinese University of Hong Kong, reviewed treatment options in mHSPC, while A/Prof Edmund Chiong, Head and Senior Consultant, Department of Urology, National University Hospital, Singapore, presented a case which was discussed by an esteemed panel of experts. This webinar was jointly organized by the Singapore Society of Oncology and the Singapore Urological Association, and supported by Astellas.
Significant advancements in the treatment of acute lymphocytic leukaemia (ALL) in children have improved their outcomes. However, ALL treatment and eradication remain a major challenge in adults. In a recent webinar, two specialists from the US discussed current ALL treatment strategies and goals of future regimens.
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Despite a 90-percent cure rate after first treatment for children with acute lymphoblastic leukaemia (ALL), approximately 10–15 percent of patients with paediatric ALL will experience relapse. [Expert Rev Anticancer Ther 2017;17:725-736] A recent webinar on the current landscape of ALL highlighted the potential of immunotherapy for paediatric patients with relapsed or refractory ALL, thus providing hope for this high-risk patient group.
Drawing from experience as a key investigator in landmark
clinical trials (including PALOMA, MONALEESA and
MONARCH), and his clinical experience with
CDK4/6 inhibitors, Dr Rafael Villanueva Vázquez shares his
insights into the current evidence of using CDK4/6 inhibitors
to treat HR+/HER2- ABC.
At the recent National Haematology Expert Meeting 2019, a panel of experts was convened to discuss the role of targeted therapy in the management of haematological malignancies. Highlights of their lectures are summarised below.
Overall survival (OS) is currently the primary
criteria in assessing the efficacy of a cancer treatment. Dr Raghav Sundar, a consultant
medical oncologist at the National University Hospital, Singapore, details the
crucial role played by tumour response in evaluating treatment efficacy, with a
focus on the multiple kinase inhibitor lenvatinib in the treatment of
hepatocellular carcinoma (HCC).
Renal cell carcinoma (RCC) is the most common primary tumour arising from the kidney, constituting approximately 80–85% of primary renal neoplasms. According to the Malaysian National Cancer Registry Report 2007–2011, RCC accounts for 62.8% of all kidney cancers nationwide. RCC typically occurs approximately 50% more commonly in men compared with women, and predominantly occurs in the sixth to eighth decade of life.
In March 2018, sublingual fentanyl citrate (SLF; Abstral®, Menarini) was made available in Malaysia. SLF is a rapid-onset opioid (ROO) indicated for the management of breakthrough cancer pain (BTcP) episodes in patients that are opioid-tolerant. In July 2018, Menarini organized an expert meeting, aptly named Malaysian Collaborative Meeting of Pain Specialists to Improve Oncology Management (MY-COMPASSION), comprising of key figures in anaesthesiology, palliative care and oncology to discuss current insights into local BTcP management. Below are highlights from the meeting.
Dr. Jeffrey Ross, Dr. Rohit Lal, Prof. Alwin Krämer, Dr. Rebecca Dent, Prof. Rafal Dziadziuszko, 20190124070000
Comprehensive genomic profiling (CGP) has emerged as a key driving force behind personalized cancer care. With the wealth of data available with CGP, medical oncologists now have in their armamentarium a tool that could enable them to provide patients with the optimum treatment. At a Roche Foundation Medicine-sponsored symposium held at the 2018 European Society of Medical Oncology (ESMO) Congress in Munich, Germany, a panel of experts reviewed key data on CGP, with a focus on the treatment of advanced cancers.
Dr. Hsu Li Yang, Dr. Tan Thuan Tong, Dr. Andrea Kwa,
08 Jan 2021
Antimicrobial resistance has become increasingly dire as the rapid emergence of drug resistance, especially gram-negative pathogens, has outpaced the development of new antibiotics. At a recent virtual symposium, Dr Hsu Li Yang, Vice Dean (Global Health) and Programme Leader (Infectious Diseases), NUS Saw Swee Hock School of Public Health, presented epidemiological data on multidrug-resistant (MDR) gram-negative bacteria (GNB) in Asia, while Dr Tan Thuan Tong, Head and Senior Consultant, Department of Infectious Diseases, Singapore General Hospital (SGH), focused on the role of ceftazidime-avibactam in MDR GNB infections. Dr Andrea Kwa, Assistant Director of Research, Department of Pharmacy, SGH, joined the panel in an interactive fireside chat, to discuss challenges, practical considerations, and solutions in MDR gram-negative infections. This Pfizer-sponsored symposium was chaired by Dr Ng Shin Yi, Head and Senior Consultant of Surgical Intensive Care, SGH.